Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 22Recurrence 3Neoplasms, Plasma Cell 3Immunoglobulin Light-chain Amyloidosis 2Amyloidosis 2Plasmablastic Lymphoma 1

Interventions

Dexamethasone 7Bortezomib 6Cyclophosphamide 5daratumumab 3Specimen Handling 34-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 3venetoclax 2dexamethasone acetate 2dexamethasone 21-phosphate 2belantamab mafodotin 2auricularum 2X-Rays 2Phantoms, Imaging 2Magnetic Resonance Spectroscopy 2Clinical Protocols 2Calcium Dobesilate 2Biopsy 2ixazomib 1Tissue Banks 1Stem Cell Transplantation 1Pharmaceutical Preparations 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × belantamab mafodotin × 90 days × Clear all
NCT05145816 2026-05-07

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

University of Texas Southwestern Medical Center

Phase 1/2 Recruiting
37 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡